CY1110744T1 - Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c - Google Patents
Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας cInfo
- Publication number
- CY1110744T1 CY1110744T1 CY20101100769T CY101100769T CY1110744T1 CY 1110744 T1 CY1110744 T1 CY 1110744T1 CY 20101100769 T CY20101100769 T CY 20101100769T CY 101100769 T CY101100769 T CY 101100769T CY 1110744 T1 CY1110744 T1 CY 1110744T1
- Authority
- CY
- Cyprus
- Prior art keywords
- prophylactic
- therapeutic treatment
- combination
- hepatitis
- virus
- Prior art date
Links
- 230000000069 prophylactic effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940123189 CD40 agonist Drugs 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 abstract 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 108700012707 hepatitis C virus NS3 Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229960001438 immunostimulant agent Drugs 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502446 | 2005-10-07 | ||
| ES200601563A ES2334472B1 (es) | 2006-06-09 | 2006-06-09 | Combinacion inmunoestimuladora para profilaxis y tratamiento de hepatitis c. |
| EP06830863A EP1949913B1 (en) | 2005-10-07 | 2006-10-05 | Immunostimulatory combination for the prophylactics and treatment of hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110744T1 true CY1110744T1 (el) | 2015-06-10 |
Family
ID=37942331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100769T CY1110744T1 (el) | 2005-10-07 | 2010-08-19 | Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100047231A1 (enExample) |
| EP (1) | EP1949913B1 (enExample) |
| JP (1) | JP2009511452A (enExample) |
| CN (1) | CN101330928B (enExample) |
| AT (1) | ATE469657T1 (enExample) |
| AU (1) | AU2006301171B9 (enExample) |
| BR (1) | BRPI0616978A2 (enExample) |
| CA (1) | CA2625506C (enExample) |
| CY (1) | CY1110744T1 (enExample) |
| DE (1) | DE602006014720D1 (enExample) |
| DK (1) | DK1949913T3 (enExample) |
| ES (1) | ES2346570T3 (enExample) |
| HR (1) | HRP20100473T1 (enExample) |
| PL (1) | PL1949913T3 (enExample) |
| PT (1) | PT1949913E (enExample) |
| RS (1) | RS51402B (enExample) |
| RU (1) | RU2431499C2 (enExample) |
| SI (1) | SI1949913T1 (enExample) |
| WO (1) | WO2007042583A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2857038B1 (en) | 2006-09-18 | 2019-04-10 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses |
| CA2704457A1 (en) | 2007-10-30 | 2009-05-07 | Walter Bottje | Compositions and methods of enhancing immune responses to flagellated bacterium |
| PT2214701T (pt) | 2007-11-01 | 2016-11-02 | Univ Guelph | Composições e métodos de potenciar respostas imunes a eimeria |
| CA2745603A1 (en) | 2008-12-03 | 2010-06-10 | Proyecto De Biomedicina Cima, S.L. | Use of phenol soluble modulins for the development of vaccines |
| CN105837691B (zh) | 2009-03-10 | 2021-06-29 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
| WO2011091255A1 (en) | 2010-01-21 | 2011-07-28 | The Board Of Trustees Of The University Of Arkansas | Vaccine vectors and methods of enhancing immune responses |
| CA2800830C (en) | 2010-06-09 | 2020-09-08 | The Board Of Trustees Of The University Of Arkansas | Vaccine and methods to reduce campylobacter infection |
| ES2758759T3 (es) | 2013-02-14 | 2020-05-06 | Univ Arkansas | Composiciones y métodos para potenciar las respuestas inmunitarias a eimeria o limitar la infección por eimeria |
| CN105142653B (zh) | 2013-03-15 | 2019-11-15 | 阿肯色大学评议会 | 增强对肠病原体免疫应答的组合物和方法 |
| JP7467027B2 (ja) | 2016-05-03 | 2024-04-15 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | 免疫刺激性ポリペプチドおよび抗原性ポリペプチドを含む酵母ワクチンベクター並びにそれを使用する方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049390A (en) * | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
| AU5285899A (en) * | 1998-07-21 | 2000-02-14 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Anti hepatitis c virus antibody and uses thereof |
| US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
| KR20070114209A (ko) * | 2000-08-17 | 2007-11-29 | 트리펩 아베 | 리바비린 함유 백신 및 이것의 사용 방법 |
| EP2258712A3 (en) * | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| EP2572714A1 (en) * | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
-
2006
- 2006-10-05 RS RSP-2010/0373A patent/RS51402B/sr unknown
- 2006-10-05 RU RU2008117328/15A patent/RU2431499C2/ru not_active IP Right Cessation
- 2006-10-05 HR HR20100473T patent/HRP20100473T1/hr unknown
- 2006-10-05 EP EP06830863A patent/EP1949913B1/en active Active
- 2006-10-05 JP JP2008534032A patent/JP2009511452A/ja active Pending
- 2006-10-05 PL PL06830863T patent/PL1949913T3/pl unknown
- 2006-10-05 US US12/083,217 patent/US20100047231A1/en not_active Abandoned
- 2006-10-05 SI SI200630732T patent/SI1949913T1/sl unknown
- 2006-10-05 AU AU2006301171A patent/AU2006301171B9/en not_active Ceased
- 2006-10-05 DK DK06830863.4T patent/DK1949913T3/da active
- 2006-10-05 AT AT06830863T patent/ATE469657T1/de active
- 2006-10-05 WO PCT/ES2006/000554 patent/WO2007042583A1/es not_active Ceased
- 2006-10-05 CA CA2625506A patent/CA2625506C/en not_active Expired - Fee Related
- 2006-10-05 BR BRPI0616978-3A patent/BRPI0616978A2/pt not_active IP Right Cessation
- 2006-10-05 PT PT06830863T patent/PT1949913E/pt unknown
- 2006-10-05 ES ES06830863T patent/ES2346570T3/es active Active
- 2006-10-05 CN CN2006800457078A patent/CN101330928B/zh not_active Expired - Fee Related
- 2006-10-05 DE DE602006014720T patent/DE602006014720D1/de active Active
-
2010
- 2010-08-19 CY CY20101100769T patent/CY1110744T1/el unknown
-
2013
- 2013-09-27 US US14/039,269 patent/US20140056943A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101330928A (zh) | 2008-12-24 |
| AU2006301171A1 (en) | 2007-04-19 |
| DE602006014720D1 (de) | 2010-07-15 |
| CN101330928B (zh) | 2012-11-14 |
| CA2625506A1 (en) | 2007-04-19 |
| RU2431499C2 (ru) | 2011-10-20 |
| HRP20100473T1 (hr) | 2010-10-31 |
| EP1949913B1 (en) | 2010-06-02 |
| RU2008117328A (ru) | 2009-11-20 |
| ATE469657T1 (de) | 2010-06-15 |
| US20100047231A1 (en) | 2010-02-25 |
| WO2007042583A1 (es) | 2007-04-19 |
| RS51402B (sr) | 2011-02-28 |
| SI1949913T1 (sl) | 2011-02-28 |
| PL1949913T3 (pl) | 2010-10-29 |
| EP1949913A1 (en) | 2008-07-30 |
| BRPI0616978A2 (pt) | 2011-07-05 |
| AU2006301171B9 (en) | 2012-03-29 |
| DK1949913T3 (da) | 2010-10-04 |
| AU2006301171B2 (en) | 2011-10-27 |
| PT1949913E (pt) | 2010-08-24 |
| ES2346570T3 (es) | 2010-10-18 |
| US20140056943A1 (en) | 2014-02-27 |
| JP2009511452A (ja) | 2009-03-19 |
| CA2625506C (en) | 2014-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110744T1 (el) | Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c | |
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
| CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
| CY1113546T1 (el) | Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων | |
| MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
| EA200700904A1 (ru) | Вакцины против вируса японского энцефалита и вируса западного нила | |
| ATE491467T1 (de) | Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans | |
| WO2008039267A3 (en) | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions | |
| EP1917033A4 (en) | VIRUS LIKE PARTICLES AS PARAMYXOVIRUS VACCINES | |
| EA200801798A1 (ru) | Виросомоподобные везикулы, содержащие антигены, производные от gp41 | |
| WO2008014521A3 (en) | Improved vaccines and methods for using the same | |
| EA201391170A1 (ru) | Терапевтическое средство на основе дрожжей для лечения хронического гепатита b | |
| EP1984388A4 (en) | HPV ANTIGENES, VACCINE COMPOSITIONS AND RELATED METHODS | |
| BRPI0520330B8 (pt) | adjuvante a base de ácido polinosínico-policitidílico | |
| FR2827605B1 (fr) | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin | |
| EA201071316A1 (ru) | Иммуномодуляция ингибиторами ингибиторов апоптоза | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
| CY1106310T1 (el) | Καθορισμος hbv αντιγονων για χρηση σε εμβολια | |
| MY149395A (en) | Pharmaceutical compound capable of induce immune protective response against dengue virus having the capsid protein of the dengue virus | |
| WO2006071896A3 (en) | Epitope-based sars vaccine | |
| MX2007002659A (es) | Composicion vacunal contra el virus de la hepatitis c. | |
| WO2007120860A3 (en) | Nanoemulsion vaccines | |
| UY31574A1 (es) | Vacunas contra la malaria |